Trial Profile
First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs ReN 003 (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Sponsors ReNeuron
- 19 Jan 2022 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.
- 19 Jan 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2022.
- 19 Jan 2022 Status changed from recruiting to active, no longer recruiting.